ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Kidney Transplant Recipients with De Novo Donor Specific Antibody is Associated with Increased Risk of Developing BK Viremia

S. Kareem1, L. Suresh2, A. Gundroo1, J. Von Viger1, S. Chang1

1Internal Medicine, University of Buffalo, Buffalo, NY, 2Pathology, University of Buffalo, Buffalo, NY

Meeting: 2020 American Transplant Congress

Abstract number: A-221

Keywords: Alloantibodies, Immunosuppression, Infection, Kidney transplantation

Session Information

Session Name: Poster Session A: Kidney: Polyoma

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Background: De novo donor specific anti-HLA antibodies (dnDSA) has profound effect on the renal graft long-term function and survival. Studies has shown identifications of dnDSA in transplant recipients and pre-emptive treatment may improve graft function. However, in the process of clearing antibodies with intensive immunosuppressive treatment can have unintended consequence of increasing infection risks.

The Objective of this study is to examine how systemic monitoring dnDSA and aggressive management protocol for positive dnDSA can effect the development of BK viremia at one single center (Erie County Medical Center).

*Methods: This is a retrospective cohort study of patients who received a kidney transplant at ECMC from 1/1/2012 to 12/31/2017. Immunosuppression consisted of thyroglobulin induction (3-4.5 mg/kg) followed by tracrolimus, MMF, and prednisone. Development of dnDSA was assessed at 1, 2, 3, 6, 12 months, and then yearly thereafter; more frequently if DSA was positive (MFI>1500). If dnDSA with MFI >3000 is present, maintenance immunosuppression was maximized, biopsy of transplant kidney was performed, and specific treatments based on biopsy findings were performed. Plasma BK PCR was screening at monthly post-transplant for 6 months, then every 3 months until 12 months post-transplant; if BK PCR is positive, the frequencies of testing is based on clinical indications. We examined and compared the development of BK viremia in patients who developed dsDSA vs. those who did not developed dsDSA.

*Results: About 12% (n=71) kidney transplant recipients developed dnDSA, with HLA class 1 occurring earlier, and HLA class 2 occurring later post-transplant. There were 489 recipients with no dsDSA . The rate of BK viremia in dsDSA recipients was 29.6%, higher than in those without dsDSA (22%, p<0.05). The dnDSA were grouped in 5 groups: transient dnDSA without intervention (N=13), transient dnDSA with intervention (N=19), persistent DSA with MFI <3000 (N=12), persistent DSA with MFI 3000-6000 (N=8), persistent DSA with MFI >6000 (N=22). In each above groups, % of BK viremia ranges between 25-31%. Factors attributed to development of dnDSA included rejection (20%:AMR, ACR, mixed), infection [16%: 9 BK, 1 UTI, 2 CMV], high cPRA/prior transplant (15%), non-adherence (11%), unknown (5%), cancer (4%).

*Conclusions: As expected, in the kidney transplant recipients with De Novo DSA who required more intense immunosuppression treatment have higher rate of BK viremia. Development of dnDSA can be a consequence of lowering immunosuppressive regimen secondary to infection such as development of BK viremia, or as consequence of increasing immunosuppression regimen secondary of rejections. Careful monitoring plasma BK PCR is warranted in transplant recipients who are receiving intensified immunosuppressive therapy.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kareem S, Suresh L, Gundroo A, Viger JVon, Chang S. Kidney Transplant Recipients with De Novo Donor Specific Antibody is Associated with Increased Risk of Developing BK Viremia [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/kidney-transplant-recipients-with-de-novo-donor-specific-antibody-is-associated-with-increased-risk-of-developing-bk-viremia/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences